Grifols Stock Earnings Reports

Grifols delivered a Q1 2026 in line with expectations: revenue €1.7bn (+3.3% cc) and adjusted EBITDA €404m (€381m reported) with margins broadly stable. Biopharma led growth (+6.8% cc), driven by strong immunoglobulin performance (IG +15.3% cc) including momentum in Gamunex and Xembify and the U.S. launch of Biotest's Yimmugo. Albumin sales were weaker in China due to prior price adjustments and elevated inventories, but management expects stabilization in H2 and continued long‑term opportunity (including expansion outside China). Alpha‑1 & specialty proteins were down quarter‑on‑quarter but management expects low‑ to mid‑single‑digit growth for 2026 and sees SPARTA trial readout (year‑end) as an important catalyst. Strategic priorities highlighted: (1) product‑mix optimization in Biopharma, (2) rapid ramp of Egyptian plasma collections (target ~1M liters in 2026 and ~3M by 2029) to lower cost per liter and rebalance global sourcing, (3) optimization of U.S. plasma network (closure of underperforming centers), (4) operational/financial turnaround support for Biotest, and (5) strict OpEx discipline. Diagnostics faced a temporary headwind from the dissolution of the Quidel Ortho joint business (with a $65m compensation to be paid over 3 years) but remains strategically important with planned ISARD serology opportunities and the Barcelona blood‑typing platform launch in Q2 2026. Free cash flow seasonally negative €8m in Q1 (improved vs prior year by €30m); net leverage improved to 4.3x. Management completed proactive refinancing, extended and upsized facilities, reduced near‑term maturities (next significant maturities Q4 2028), and reiterated commitment to deleveraging while retaining capital allocation optionality (including potential share buybacks and evaluated U.S. Biopharma IPO process which is at an early stage and currently non‑commentable). Overall message: execution on strategic levers and balance‑sheet strengthening position Grifols to hit 2026 targets (adjusted EBITDA margin goal of at least 25%, adjusted EBITDA growth 5–9% cc, and FCF target €500–575m for the full year).